To order this 485+ page report, which features 195+ figures and 200+ tables, please visit this link

The USD 8 billion (by 2030) financial opportunity within the synthetic lethality-based drugs and targets market has been analyzed across the following segments:
 Type of molecule
 Small Molecule
 Biologic

 Target disease indication
 Breast Cancer
 Colorectal Cancer
 Fallopian Tube Cancer
 Gastric Cancer
 Head and Neck Cancer
 Lung Cancer
 Ovarian Cancer
 Peritoneal Cancer
 Others

 Type of synlet target
 APE1 / Ref-1
 Chk1
 GLS1
 PARP
 Pol θ
 PP2A
 Wee1

 Route of administration
 Oral
 Intravenous

 Key geographical regions
 North America
 Europe
 Asia Pacific
 Rest of the World

The https://www.rootsanalysis.com/reports/view_document/synthetic-lethality-based-drugs-and-targets-market-2019-2030-focus-on-dna-repair-including-parp-inhibitors-and-other-novel-cellular-pathways/267.html, report features the following companies, which we identified to be key players in this domain:
 AbbVie
 AstraZeneca
 AtlasMedx
 BeiGene
 Chordia Therapeutics
 Clovis Oncology
 GlaxoSmithKline
 IDEAYA Biosciences
 Mission Therapeutics
 Pfizer
 Repare Therapeutics
 Sierra Oncology
 SyntheX Labs

Table of Contents

1. Preface

2. Executive Summary

3. Introduction to DNA Damage and Repair Systems

4. Introduction to Synthetic Lethality

5. Market Overview

6. Company Profiles

7. Emerging Trends on Social Media

8. Publication Analysis

9. Abstract Analysis

10. Academic Grants Analysis

11. Funding and Investment Analysis

12. Target Benchmark Analysis

13. Role of Companion Diagnostics in Synthetic Lethality

14. Market Forecast

15. Concluding Remarks

16. Executive Insights

17. Appendix 1: Tabulated Data

18. Appendix 2: List of Companies and Organizations


To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/synthetic-lethality-based-drugs-and-targets-market-2019-2030-focus-on-dna-repair-including-parp-inhibitors-and-other-novel-cellular-pathways/267.html

Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
[email protected]